These 5 Stocks Under $10 Are Poised To Explode

4. Caribou Biosciences, Inc. (NASDAQ:CRBU)

Share Price as of December 14: $6.41
Share Price Upside Potential: 289.38%
Number of Hedge Funds: 21

Caribou Biosciences, Inc. (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company that develops genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors. Caribou Biosciences, Inc. (NASDAQ:CRBU)’s lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

Caribou Biosciences, Inc. (NASDAQ:CRBU) has recouped a significant chunk of the losses accrued in the year and is only down by 10%. The consensus rating on Wall Street is a Buy with a $22 price target, implying 289.38% upside potential. According to Insider Monkey’s third-quarter database, 21 hedge funds were long Caribou Biosciences, Inc. (NASDAQ:CRBU), compared to 15 funds in the last quarter.

Follow Caribou Biosciences Inc.

[/company-follow-email]